Antiviral agents for the treatment of COVID-19: Progress and challenges.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35474740.
- Also identified by DOI 10.1016/j.xcrm.2022.100549 and PMC identifier 8831133.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The COVID-19 pandemic has seen clinical development and use of antiviral therapies at an unprecedented speed. Antiviral therapies have greatly improved the clinical outcome in COVID-19 patients, especially when administered early after diagnosis. Here, we discuss the successes and challenges of COVID-19 antiviral therapies and lessons for future pandemics.
Medical subject headings
- Influenza, Human
- COVID-19 Drug Treatment